SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-115796
Filing Date
2023-11-08
Accepted
2023-11-08 17:03:26
Documents
18
Period of Report
2023-11-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2330052d1_8k.htm   iXBRL 8-K 32536
2 EXHIBIT 1.1 tm2330052d1_ex1-1.htm EX-1.1 294897
3 EXHIBIT 5.1 tm2330052d1_ex5-1.htm EX-5.1 8979
4 EXHIBIT 99.1 tm2330052d1_ex99-1.htm EX-99.1 9878
5 EXHIBIT 99.2 tm2330052d1_ex99-2.htm EX-99.2 10481
9 GRAPHIC tm2330052d1_ex99-1img001.jpg GRAPHIC 3070
10 GRAPHIC tm2330052d1_ex99-2img001.jpg GRAPHIC 3070
  Complete submission text file 0001104659-23-115796.txt   622392

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA cldx-20231107.xsd EX-101.SCH 3048
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE cldx-20231107_lab.xml EX-101.LAB 34240
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cldx-20231107_pre.xml EX-101.PRE 22381
12 EXTRACTED XBRL INSTANCE DOCUMENT tm2330052d1_8k_htm.xml XML 3244
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-15006 | Film No.: 231389089
SIC: 2835 In Vitro & In Vivo Diagnostic Substances